BMRN
$63.94
▼ −1.75%09/18 O 65.25 H 65.29 L 63.84 C 63.94 ▼ −1.75%
Vol 4.5M RS 65
Vol 4.5M RS 65
RS rating65
Now vs pivot (%)−13.02%
Tightening (ATR ratio)0.97×
Volume dry-up1.04×
Up/down volume, net0.13
From 52-week high10%
forming
BioMarin Pharmaceuticals Inc
BMRN · Pharmaceutical Preparations · $12.4B
Cooling off
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The four are not in order. That is a description of where the averages sit, not a view about what happens next.
The read
The base has run 77.2 weeks and fell 33% from its ceiling at its deepest. The pivot is $73.51, and the stock closed 13.0% below it. Its relative strength rating is 65.
Peers
Catalyst roadmap
- Earningstentativein 38dQuarterly earningsOct 26, 2026
- EarningstentativeLLY · competitorin 41dLLY reportsOct 29, 2026
Flagged by the market sweep
A director or officer changedFiling · 2026-09-15
5.02
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.
In the news
BioMarin Stops Voxzogo Development for Noonan SyndromeZacks Investment Research · 3 days agoHow BioMarin Turned a Competitive Threat Into a Royalty-Bearing AssetZacks Investment Research · 2026-09-03
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray